Benjamin Nelson

Ben brings Dark Horse clients a complimentary blend of strategy, due diligence, and commercial execution specifically suited to the unique challenges of the cell and gene therapy industry. Developing and implementing go-to market strategies for products like the Lovo Cell Processing System and industry partnerships such as ScaleReady, he has been a key leader in C&GT organizations for more than seven years.

Before joining DHC, Ben was responsible for the global strategic marketing and commercial operations efforts at ScaleReady, a joint venture between Fresenius Kabi, Bio-Techne, and Wilson Wolf. He was a key member of the deal team, structuring the partnership, go-to market strategy, and tactical execution of the launch. Prior to the partnership’s go-live date, Ben established an end-to-end integrated ERP and CRM system for order processing, finance, and quality management SOPs. In addition, he led the creation of new branding and positioning showcasing ScaleReady’s unique and modular manufacturing platform.

Prior to ScaleReady, Ben was responsible for global strategic marketing for Fresenius Kabi’s cell therapy team. Here, he helped launch the Lovo Cell Processing System which has since become a widely adopted instrument for CGT organizations across the globe. Before joining the Cell Therapy team, Ben was part of Fresenius’s corporate strategy and M&A group responsible for product due diligence and deal modeling across a range of Medical Device segments such as infusion pumps, plasma centers, and blood centers.